144 related articles for article (PubMed ID: 28717903)
21. Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival.
Akslen LA; Varhaug JE
Cancer; 1995 Nov; 76(9):1643-54. PubMed ID: 8635070
[TBL] [Abstract][Full Text] [Related]
22. Expression of HIF-1α and HIF-2α correlates to biological and clinical significance in papillary thyroid carcinoma.
Liu YM; Ying SP; Huang YR; Pan Y; Chen WJ; Ni LQ; Xu JY; Shen QY; Liang Y
World J Surg Oncol; 2016 Feb; 14(1):30. PubMed ID: 26846782
[TBL] [Abstract][Full Text] [Related]
23. [Study on the relationship between ultrasonographic features of papillary thyroid carcinoma and central cervical lymph node metastasis].
Wang XQ; Wei W; Wei X; Xu Y; Wang HL; Xing XJ; Zhang S
Zhonghua Zhong Liu Za Zhi; 2018 Mar; 40(3):196-200. PubMed ID: 29575838
[No Abstract] [Full Text] [Related]
24. Neuropilin-2 promotes growth and progression of papillary thyroid cancer cells.
Lee G; Kang YE; Oh C; Liu L; Jin Y; Lim MA; Won HR; Chang JW; Koo BS
Auris Nasus Larynx; 2020 Oct; 47(5):870-880. PubMed ID: 32381353
[TBL] [Abstract][Full Text] [Related]
25. ret/PTC expression may be associated with local invasion of thyroid papillary carcinoma.
Miki H; Kitaichi M; Masuda E; Komaki K; Yamamoto Y; Monden Y
J Surg Oncol; 1999 Jun; 71(2):76-81; discussion 81-2. PubMed ID: 10389862
[TBL] [Abstract][Full Text] [Related]
26. Lymphovascular invasion is associated with lateral cervical lymph node metastasis in papillary thyroid carcinoma.
Kim JM; Kim TY; Kim WB; Gong G; Kim SC; Hong SJ; Shong YK
Laryngoscope; 2006 Nov; 116(11):2081-5. PubMed ID: 17075398
[TBL] [Abstract][Full Text] [Related]
27. Risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma: A meta-analysis.
Vorasubin N; Nguyen C; Wang M
Ear Nose Throat J; 2016 Feb; 95(2):73-7. PubMed ID: 26930333
[TBL] [Abstract][Full Text] [Related]
28. Expression of VHL tumor suppressor mRNA and miR-92a in papillary thyroid carcinoma and their correlation with clinical and pathological parameters.
Todorović L; Stanojević B; Mandušić V; Petrović N; Živaljević V; Paunović I; Diklić A; Saenko V; Yamashita S
Med Oncol; 2018 Jan; 35(2):17. PubMed ID: 29340905
[TBL] [Abstract][Full Text] [Related]
29. [Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].
Shi CL; Guo Y; Lyu YC; Nanding ZABYS; Gao WC; Shi TF; Qin HD; Liu SY
Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):361-366. PubMed ID: 28535653
[No Abstract] [Full Text] [Related]
30. Expression of ki67 in papillary thyroid microcarcinoma and its clinical significance.
Zhou Y; Jiang HG; Lu N; Lu BH; Chen ZH
Asian Pac J Cancer Prev; 2015; 16(4):1605-8. PubMed ID: 25743839
[TBL] [Abstract][Full Text] [Related]
31. Number of central lymph node metastasis for predicting lateral lymph node metastasis in papillary thyroid microcarcinoma.
Zeng RC; Zhang W; Gao EL; Cheng P; Huang GL; Zhang XH; Li Q
Head Neck; 2014 Jan; 36(1):101-6. PubMed ID: 23900787
[TBL] [Abstract][Full Text] [Related]
32. Histomorphological factors in the risk prediction of lymph node metastasis in papillary thyroid carcinoma.
Chung YJ; Lee JS; Park SY; Park HJ; Cho BY; Park SJ; Lee SY; Kang KH; Ryu HS
Histopathology; 2013 Mar; 62(4):578-88. PubMed ID: 23379688
[TBL] [Abstract][Full Text] [Related]
33. The prognostic value of the metastatic lymph node ratio and maximal metastatic tumor size in pathological N1a papillary thyroid carcinoma.
Jeon MJ; Yoon JH; Han JM; Yim JH; Hong SJ; Song DE; Ryu JS; Kim TY; Shong YK; Kim WB
Eur J Endocrinol; 2013 Feb; 168(2):219-25. PubMed ID: 23161752
[TBL] [Abstract][Full Text] [Related]
34. Predictive factors for ipsilateral or contralateral central lymph node metastasis in unilateral papillary thyroid carcinoma.
Koo BS; Choi EC; Yoon YH; Kim DH; Kim EH; Lim YC
Ann Surg; 2009 May; 249(5):840-4. PubMed ID: 19387316
[TBL] [Abstract][Full Text] [Related]
35. Tumor-associated macrophages promote the metastatic potential of thyroid papillary cancer by releasing CXCL8.
Fang W; Ye L; Shen L; Cai J; Huang F; Wei Q; Fei X; Chen X; Guan H; Wang W; Li X; Ning G
Carcinogenesis; 2014 Aug; 35(8):1780-7. PubMed ID: 24608042
[TBL] [Abstract][Full Text] [Related]
36. Strong expression of HBME-1 associates with high-risk clinicopathological factors of papillary thyroid carcinoma.
Dencic TM; Savin SB; Selemetjev SA; Paskas SD; Zivaljevic VR; Bozic VD; Cvejic DS
Pathol Oncol Res; 2015 Jul; 21(3):735-42. PubMed ID: 25577274
[TBL] [Abstract][Full Text] [Related]
37. Clinical risk factors for central lymph node metastasis in papillary thyroid carcinoma: a systematic review and meta-analysis.
Qu H; Sun GR; Liu Y; He QS
Clin Endocrinol (Oxf); 2015 Jul; 83(1):124-32. PubMed ID: 25130203
[TBL] [Abstract][Full Text] [Related]
38. Central lymph node metastasis in cN0 papillary thyroid carcinoma.
Wu Y; Gu J; Shang J; Wang W; Wang K
J BUON; 2013; 18(3):733-8. PubMed ID: 24065492
[TBL] [Abstract][Full Text] [Related]
39. Clinical implications of bilateral lateral cervical lymph node metastasis in papillary thyroid cancer: a risk factor for lung metastasis.
Lee YS; Lim YS; Lee JC; Wang SG; Kim IJ; Son SM; Lee BJ
Ann Surg Oncol; 2011 Nov; 18(12):3486-92. PubMed ID: 21553141
[TBL] [Abstract][Full Text] [Related]
40. The expression of monocyte chemotactic protein-1 in papillary thyroid carcinoma is correlated with lymph node metastasis and tumor recurrence.
Tanaka K; Kurebayashi J; Sohda M; Nomura T; Prabhakar U; Yan L; Sonoo H
Thyroid; 2009 Jan; 19(1):21-5. PubMed ID: 19072670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
